|
DrugPatentWatch concentrates deep knowledge on more than 6,400 small-molecule drugs and 2,300 generic ingredients from 1,700 branded and generic pharmaceutical companies and 700 suppliers, and more than 4,300 active and expired US patents and 74,000 international patents spanning 93 countries and regional patent offices. |
Tradename: NIMBEX
Summary for Tradename: NIMBEX
|
| |||||||||
Clinical Trials for: NIMBEXStudy of Cisatracurium and Sufentanil Consumption Using a Closed Loop Computer Control Infusion System Status: Recruiting Condition: The Intraoperative Effect of Dexmedetomidine on Cisatracurium Infusion Consumption and Its Recovery Index.; Effect of Dexmedetomidine on Sufentanil Consumption.; Quantitative Analysis of Cisatracurium Infusion Requirements, Sufentanil Consumption and Recovery Index in Different Age Groups. Comparison Between Cisatracurium and Rocuronium in Terms of Recovery of the Muscular Strength in the Postoperative Phase After Surgery and General Anaesthesia Status: Recruiting Condition: Postoperative Residual Curarization; Residual Neuromuscular Block Comparison of the Effects of Vecuronium and Cisatracurium on Electrophysiologic Monitoring During Neurosurgery Status: Recruiting Condition: Motor Evoked Potential Monitoring; General Anesthesia; Neurosurgery; Brain Tumor; Spine Tumor; Cerebral Aneurysm Effect of Cisatracurium Versus Atracurium on Intraocular Pressure in Patients Underwent General Anesthesia Status: Completed Condition: Intraocular Pressure Analysis of Cisatracurium Consumption in Balanced Anesthesia With 1% Sevoflurane, and With Only Sevoflurane, Using a Closed-loop Computer Controlled System Infusion. Status: Completed Condition: Drug Interaction Potentiation A Study of Residual Curarization Incidence in China Status: Not yet recruiting Condition: Perioperative/Postoperative Complications; PORC (Postoperative Residual Curarization) Effect of Nitrous Oxide on Cisatracurium Infusion Demands Status: Completed Condition: Neuromuscular Blocking Agents Comparison of Rocuronium and Org 25969 With Cisatracurium and Neostigmine (19.4.310)(P05931)(COMPLETED) Status: Completed Condition: Anesthesia, General Effects of Neuromuscular Blocking Agents (NMBA) on the Alteration of Transpulmonary Pressures at the Early Phase of Acute Respiratory Distress Syndrome (ARDS) Status: Recruiting Condition: Acute Respiratory Distress Syndrome Systematic Early Use of Neuromuscular Blocking Agents in ARDS Patients Status: Completed Condition: ARDS Courtesy of ClinicalTrials.org See more clinical trials for this drug | ||||||||||
Glossary
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Type | RLD | Patent No. | Product | Substance | Delist_Flag | Patent Expiration | Exclusivity Expiration | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Abbvie | NIMBEX | cisatracurium besylate | INJECTABLE; INJECTION | 020551 | Dec 15, 1995 | RX | Yes | 5,453,510 | <disabled> | <disabled> | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Abbvie | NIMBEX PRESERVATIVE FREE | cisatracurium besylate | INJECTABLE; INJECTION | 020551 | Dec 15, 1995 | RX | Yes | 5,453,510 | <disabled> | <disabled> | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| The preview shows a limited data set. Complete access is available with a Subscription | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
Paragraph IV activity for: NIMBEX
| Drugname | Dosage | Strength | RLD | Submissiondate |
| cisatracurium besylate (preserve free) | Injection | 2 mg/mL, 5 mL vial and 10 mg/mL, 20 mL vial | Nimbex | 8/4/2009 |
| cisatracurium besylate (multi-dose) | Injection | 2 mg/mL, 10 mL vial | Nimbex | 8/12/2009 |
« Back to Dashboard
DrugPatentWatch Archives
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Connect with Social Media:
Copyright © 2002-2013 thinkBiotech LLC. ISSN: 2162-2639
`abc